Hepa Lichtenstein

Hepa Lichtenstein is a cutaneous product that contains heparin sodium as its active ingredient. It is marketed in the European Union and is classified as an anticoagulant and antithrombotic agent. The preparation is intended for topical application to support the body’s natural anticoagulant pathways. Heparin sodium works by enhancing antithrombin III activity, which reduces clot formation. The product is supplied without a listed strength and is intended for use under professional guidance.

Hepa Lichtenstein is used as a topical anticoagulant to help prevent the formation of blood clots in specific clinical situations.

- Prophylaxis of superficial thrombophlebitis after minor surgical procedures. - Adjunctive therapy for patients at risk of venous thromboembolism who require localized anticoagulation. - Support in the management of catheter‑related thrombosis when systemic anticoagulation is not indicated. - Prevention of clot formation in skin grafts or flap procedures.

Topical application of heparin sodium may be associated with local and systemic effects.

Common: - Mild skin irritation at the application site. - Redness or erythema. - Minor bruising. - Localized itching. - Small amount of bleeding from the site.

Serious: - Severe skin necrosis. - Allergic reactions such as urticaria or angioedema. - Uncontrolled bleeding or hematoma formation. - Heparin‑induced thrombocytopenia (HIT) in susceptible individuals.

When using Hepa Lichtenstein, several precautionary measures should be considered to minimize risk.

- Assess the patient’s bleeding risk before initiating therapy. - Avoid use on open wounds or infected skin. - Do not apply excessive amounts; follow healthcare professional guidance. - Monitor for signs of skin necrosis or allergic reaction. - Use with caution in patients with known heparin sensitivity. - Consider renal or hepatic impairment may affect metabolism.

Heparin sodium can interact with other agents that affect coagulation or platelet function.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants). - Systemic thrombolytic agents (e.g., alteplase). - High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs). - Intravenous or subcutaneous heparin therapy.

Use with caution: - Antiplatelet drugs such as clopidogrel. - Herbal supplements that may increase bleeding risk (e.g., ginkgo, garlic). - Vitamin K antagonists, requiring close monitoring of coagulation parameters. - Patients undergoing invasive procedures.